Tango Therapeutics
Business Services · Massachusetts, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
201 Brookline Ave Ste 901, Boston, Massa...Phone Number
(857) 320-4900Website
www.tangotx.comRevenue
$57 MillionStock Symbol
TNGXIndustry
ZI Rank: 2
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
4
3
1
1
2
About Tango Therapeutics
Founded in 2017, Tango Therapeutics is a biotechnology company discovering and developing novel medicines. It focused on the discovery and development of novel cancer therapies. The company is based in Boston, Massachusetts, United States.Explore more
Tango Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Tango Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Tango Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Tango Therapeutics has new funding data
Check out if Tango Therapeutics is spiking on competitors!
Product Launch: Get notified when Tango Therapeutics launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Tango Therapeutics recently announced quarterly report
Website visits: Recent activity has been detected on your website
Tango Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Tango Therapeutics had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Tango Therapeutics
Recommended Actions
Reach out to Masked Content who joined Tango Therapeutics as Masked Content
Find more new buyers
Compare Similar Companies to Tango Therapeutics
Compare insights from companies similar to Tango Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Tango Therapeutics
$57M
51-200
Public
$455M
2017
SS
Sandra SuteraVice President, Head of Program and Portfolio Management, Chief of Staff To the President of Research and Development
Company Profile Activity
Activity Insights
Tango Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Tango Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Tango Therapeutics.
Tango Therapeutics financials insights
Gather financial insights about Tango Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Private Equity
$50M
Other Financing Round
$165M
2025
Stock/Share Issuance
$225M
Private Equity
$15M
Tango Therapeutics Tech Stack
A closer look at the technologies used by Tango Therapeutics
See more technologies
Most Recent Scoops
Open Position
Project
Tango Therapeutics has announced plans to share single-agent Boca Medistat data in non-small cell lung cancer during the current year, with the company evaluating development paths in both the second-line and first-line settings for patients with overlapping MTAP deletion and RAS mutation, representing an addressable population of approximately 5,000 patients annually.
Medical Research, Pharmaceuticals
Project
Tango Therapeutics has reported a 49% single-agent overall response rate for Boca Medistat in a histology-selected patient population, including confirmed partial responses in three of three patients with head and neck squamous cell carcinoma, and has indicated that a histology-agnostic development path is among the topics to be discussed with regulators.
Medical Research, Pharmaceuticals
Hiring Plans
Tango Therapeutics has more open roles in Operations than it has had at any time in the past 12 months.
Hiring Plans
Person-Based
Earnings, Medical Research, Pharmaceuticals, Clinical Operations, Finance
Tango Therapeutics News & Media
Tango Therapeutics Announces Pricing of $600 Million Upsized Public Offering
BOSTON, June 09, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (“Tango”) (Nasdaq: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, announced today the pricing of an underwritten offering of 18,166,667 shares of its common stock and pre-funded warrants to purchase up to 1,833,395 shares of its common stock (the “Offering”). The offering price of each share of common stock is $30.00. The offering price of eTango Therapeutics Announces Proposed $500 Million Public Offering
BOSTON, June 08, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (“Tango”) (Nasdaq: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, announced today the launch of an underwritten public offering (the “Offering”) of $500 million of its common stock. All shares of common stock to be sold in the Offering will be offered by Tango. Tango also intends to grant the underwriters a 30-day option to purchaseTango Therapeutics Announces Combination of Vopimetostat and Daraxonrasib Demonstrated 92% Objective Response Rate in Pancreatic Cancer
Initial data from ongoing Phase 1/2 trial in patients with second and third line PDAC treated with vopimetostat and daraxonrasib showed 6-month PFS rate of 90% (median PFS not yet reached) suggesting durability of clinical benefitTango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, June 05, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that, effective June 1, 2026, the Compensation Committee of Tango Therapeutics' Board of Directors granted a non-qualified stock option to purchase 170,000 shares of its common stock and 40,000 restricted stock units (RSUs) to a new employee under Tango Therapeutics' 2023 Inducement Plan.
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Tango Therapeutics
Sign Up For FreeTo access detailed company insights
Founded in 2017, Tango Therapeutics is a biotechnology company discovering and developing novel medicines. It focused on the discovery and development of novel cancer therapies. The company is based in Boston, Massachusetts, United States.... Read More
